For the year ending 2025-12-31, LMAT had $2,634K increase in cash & cash equivalents over the period. $74,468K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net sales | 249,602 |
| Cost of sales | 71,063 |
| Gross profit | 178,539 |
| Selling expense | 49,434 |
| Marketing expense | 5,030 |
| Administrative expense | 28,243 |
| Finance expense | 11,040 |
| Management information systems expense | 2,741 |
| Research and development expense | 4,039 |
| Process engineering expense | 2,630 |
| Regulatory and clinical expense | 7,470 |
| Restructuring expense | 0 |
| Other expense (income), net | -10,178 |
| Net income | 57,734 |
| Depreciation and amortization | 10,418 |
| Stock-based compensation | 7,826 |
| Amortization of issuance costs on convertible senior notes | 873 |
| Provision for inventory write-downs | 2,661 |
| Provision (benefit) for deferred income taxes | 2,312 |
| Loss on divestitures | 0 |
| Provision for credit losses | 817 |
| Unrealized loss on equity investments | -535 |
| Foreign currency transaction effect on income | 176 |
| Accounts receivable | 2,947 |
| Inventory and other deferred costs | 7,223 |
| Prepaid expenses and other assets | -2,426 |
| Accounts payable and other liabilities | 4,198 |
| Accrued interest | 1,797 |
| Net cash provided by operating activities | 81,251 |
| Purchases of short-term marketable securities | 641,329 |
| Purchases of property and equipment | 6,783 |
| Payments related to acquisitions, net of cash acquired | 1,899 |
| Proceeds from sales of short-term marketable securities | 585,070 |
| Net cash used in investing activities | -64,941 |
| Proceeds from issuance of convertible senior notes, net of issuance costs paid of 3,234 | 0 |
| Costs paid related to issuance of convertible senior notes-Convertible Senior Notes | 0 |
| Common stock cash dividend paid | 18,109 |
| Proceeds from stock option exercises | 6,823 |
| Payment of withholding taxes in connection with net settlement of equity awards | 1,821 |
| Deferred payments for acquisitions | 1,433 |
| Net cash (used in) provided by financing activities | -14,540 |
| Effect of exchange rate changes on cash and cash equivalents | 864 |
| Net increase in cash and cash equivalents | 2,634 |
| Cash and cash equivalents at beginning of period | 25,610 |
| Cash and cash equivalents at end of period | 28,244 |
LEMAITRE VASCULAR INC (LMAT)
LEMAITRE VASCULAR INC (LMAT)